Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 12/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PDE6D | O43924 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222602 | 1.00 | HMGCR (0.49) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL13456278 | 0.92 | HMGCR (0.45) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL14243567 | 0.91 | HMGCR (0.45) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL4079327 | 0.88 | HMGCR (0.56) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL11295264 | 0.88 | HMGCR (0.56) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL1021915 | 0.88 | HMGCR (0.56) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL1022804 | 0.88 | HMGCR (0.56) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL14340395 | 0.88 | HMGCR (0.54) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL4079332 | 0.88 | HMGCR (0.56) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL1021914 | 0.88 | HMGCR (0.56) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526099-B1 | IMPROVED PROCESS FOR THE PREPARATION OF AMIDE INTERMEDIATES AND THEIR USE THEREOF | MSN LAB LTD (IN) | 2016-03-30 | — | — | EP | claimed |
| US-20120323005-A1 | Process For The Preparation Of Amide Intermediates And Their Use Thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2012-12-20 | — | — | US | claimed |
| EP-2526099-B1 | IMPROVED PROCESS FOR THE PREPARATION OF AMIDE INTERMEDIATES AND THEIR USE THEREOF | MSN LAB LTD (IN) | 2016-03-30 | — | — | EP | disclosed |
| US-8987444-B2 | Process for the preparation of amide intermediates and their use thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-03-24 | — | — | US | disclosed |
| US-20120323005-A1 | Process For The Preparation Of Amide Intermediates And Their Use Thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2012-12-20 | — | — | US | disclosed |
| WO-2011086584-A2 | IMPROVED PROCESS FOR THE PREPARATION OF AMIDE INTERMEDIATES AND THEIR USE THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323005-A1 | Process For The Preparation Of Amide Intermediates And Their Use Thereof | CETP, LCAT, APOB | HMGCR 4/4885HDAC1 473/4885HDAC2 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.